


TOP 10 ONCOGENIC MARKERS IN NSCLC FOR 2022:

Evolution of Tumor
Testing Technologies,
Novel Treatments,
and Trials!



IN-PERSON + VIRTUAL SATELLITE SYMPOSIUM

FRIDAY, JUNE 3, 2022

7:00 PM - 9:00 PM CDT

Meet the Faculty
Session:

9:00 PM - 9:45 PM

PROGRAM CHAIR

Charu Aggarwal, MD, MPH

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

WELCOME

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!**

Our ever-advancing understanding of oncogenic drivers in non-small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including those targeting EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK and RET.

This CME satellite symposium will focus on strategies to improve the application and interpretation of testing in NSCLC to identify actionable alterations as well as the latest data on the safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.

In working together with PER®, we strive to make this activity, along with all PER®'s accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with NSCLC.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Charu Aggarwal, MD, MPH

Leslye M. Heisler Associate Professor of Medicine
Associate Director, Penn Center for Precision Medicine
Physician Leader, Airways Malignancies Clinical Research
University of Pennsylvania
Philadelphia, PA

Phil Talamo, CHCP

President
Physicians' Education Resource®, LLC
Cranbury, NJ

AGENDA

7:00 PM	Welcome, Introductions, and Presession Survey	Charu Aggarwal, MD, MPH
7:10 PM	Uncovering Oncogenic Markers in Advanced NSCLC: Update on Testing Technologies	Dara Aisner, MD, PhD
Top 10 Biomarkers in Advanced NSCLC: What You Need to Know		
7:30 PM	• ROS1 • RET • NTRK	D. Ross Camidge, MD, PhD
7:45 PM	Audience Q&A	
7:50 PM	• NRG1 Fusions • HER3 in NSCLC • TROP2	Charu Aggarwal, MD, MPH
8:05 PM	Audience Q&A	
8:10 PM	• EGFR Exon 20 • Insertions HER2	Julia Kathleen Rotow, MD
8:25 PM	Audience Q&A	
8:30 PM	• MET Exon 14 Skipping and MET Alterations • KRAS	Balazs Halmos, MD, MS
8:45 PM	Audience Q&A	
8:50 PM	Conclusions, Postsession Survey, and Final Thoughts	Charu Aggarwal, MD, MPH
9:00-9:45 PM	Faculty After Hours!	All Faculty

Upcoming PER® Conferences

2022

	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10



Virtual Conference



In-Person + Virtual Conference

Target Audience

This educational activity is directed toward medical oncologists, pulmonologists, pathologists, surgeons, nurses, pharmacists, and other oncology health care professionals.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Determine actionable biomarkers to inform decision-making in the management of advanced NSCLC
- Explain the role of testing and ways to facilitate diagnosis for NSCLC treatment
- Describe efficacy and safety of investigations that used actionable biomarkers to personalize NSCLC care
- Evaluate emerging targets and biomarker-driven strategies undergoing late-stage evaluation for use in advanced NSCLC

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER® website by 12 PM EDT on Monday, June 6. To access these materials, please visit <http://www.gotoper.com/nsclc0622iss-esyll>

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<http://www.gotoper.com/nsclc0622iss-eval>

The online evaluation and request for credit will be available immediately following the program and will remain available until September 3, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live symposium for a maximum of 2.0 *AMA PRA Category 1 Credits™*, and .75 *AMA PRA Category 1 Credits™* for the Meet the Faculty Session. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours for participation in the live symposium and .75 Contact Hours for the Meet the Faculty Session.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Amgen, Inc; Elevation Oncology; Guardant Health; Janssen Biotech, Inc; administered by Janssen Scientific Affairs, LLC; Kinnate Biopharma; and Turning Point Therapeutics, Inc.

Thank you for attending **Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.

ACTIVITY OVERVIEW

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Other
Charu Aggarwal, MD, MPH	Recipient- Institution: AstraZeneca/ MedImmune Genentech/ Roche, Incyte, MacroGenics, Merck Sharp & Dohme	AstraZeneca, Blueprint Genetics, Boehringer Ingelheim, Celgene, Daiichi Sankyo/ Regeneron/ Sanofi, Eisai, Genentech, Janssen, Lilly, Merck, NalGene, Pfizer, Shionogi, Turning Point Therapeutics	
Dara Aisner, MD, PhD	Genentech	Genentech, Blueprint Medicines, Loxo Oncology, Sanofi Genzyme	
D. Ross Camidge, MD, PhD	Inivata	2022: Apollomics (SRC), AstraZeneca/Daiichi (ILD adjudication committee), BeiGene (DSMB) EMD Serono, Medtronic, Mersana (ILD adjudication committee), Mirati, Onkure, Roche 2021: AbbVie, Amgen, AnHeart, Apollomics (SRC), AstraZeneca (SRC/ SC), BeiGene (DSMC), Bio-Thera (DSMB), Blueprint, Daiichi-Sankyo (ILD adjudication committee), Elevation (SRC), Eli Lilly (DSMB and NCCN), EMD Serono, Helsinn (DSMB), Hengrui (DSMC), Janssen, Kestrel (SAB, Shares), Mersana, Nuvalent (SAB), Puma (NCCN), Ribon, Roche/ Genentech, Sanofi, Seattle Genetics, Takeda, Turning Point 2020: Amgen, Anchiarno (SAB), Apollomics (SRC), AstraZeneca, Bio-Thera (DSMB), BMS, Daiichi-Sankyo (ILD adjudication committee), Eisai, EMD Serono, Elevation (SRC), Eli Lilly, GSK, Helsinn, Janssen, Mersana, Onkure, Pfizer, Qilu, Roche, Sanofi, Seagen, Takeda	Company sponsored trials at institution (PI roles): 2020-22: AbbVie, AstraZeneca, Blueprint, Dizal, Inhibrx, Karyopharm, Pfizer, Phosphatin, PsiOxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point, Verastem
Balazs Halmos, MD, MS	AbbVie, Advaxis, Amgen, AstraZeneca, Boehringer-Ingelheim, Daiichi, GSK, Janssen, Jazz, Merck, Novartis	Apollomics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech/Roche, Lilly, Merck, Novartis, Pfizer, Takeda, TPT Therapeutics, Veracyte	

**Information accurate at time of posting*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair**Charu Aggarwal, MD, MPH**

Leslye M. Heisler Associate Professor of Medicine
Associate Director, Penn Center for Precision Medicine
Physician Leader, Airways Malignancies Clinical Research
University of Pennsylvania
Philadelphia, PA

Charu Aggarwal, MD, MPH, is the Leslye M. Heisler Associate Professor of medicine in the hematology-oncology division at Perelman School of Medicine at the University of Pennsylvania. She is an active member of the Abramson Cancer Center (ACC) where she serves as physician leader for the clinical research program for airways malignancies.

Dr. Aggarwal specializes in the management of patients with lung and head and neck cancer, with a specific and clinical research focus on the development of novel immunotherapeutic approaches, and the discovery and application of biomarkers to guide therapy and monitor treatment. She serves as the local and national principal investigator for multiple clinical trials focusing on the development of targeted immunotherapeutic approaches, including cellular therapy and CAR-T for solid tumors. Aggarwal has led the development of a DNA plasmid-based HPV-specific immunotherapy for HPV-associated head and neck cancers. She is actively involved in evaluating the role of plasma-based next-generation gene sequencing in management of patients with metastatic lung cancer.

She has extensive experience in the planning, design, and execution of clinical trials, is an active member of Eastern Cooperative Oncology Group, and has served as a national substudy chair for SWOG-NCI's LUNG-MAP. She has served on the annual meeting Scientific Program Committee of American Society of Clinical Oncology (ASCO), ASCO Education Committee, NCI Head and Neck Metastatic Task Force Steering Committee, and ACC's Data Safety and Monitoring Committee. Aggarwal's ultimate goal as a clinical and translational investigator is to perform patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with lung and head and neck cancer.

Faculty

**Dara Aisner MD, PhD**

Associate Professor of Pathology
 Medical Director, Colorado Molecular Correlates Laboratory
 University of Colorado Anschutz Medical Campus
 Aurora, CO

Dara Aisner, MD, PhD, is board certified in Anatomic Pathology, Molecular Genetic Pathology and Clinical Informatics. She completed her MD/PhD at UT Southwestern, followed by residency at NCI and fellowships in surgical pathology and molecular genetic pathology at Penn.

She is the Medical Director of the Colorado Molecular Correlates Laboratory, an AP-based molecular testing lab at the University of Colorado Department of Pathology and also signs out thoracic pathology.

Dr. Aisner has participated in several guidelines related to molecular testing in NSCLC, including the 2018 revision to the CAP/IASLC/AMP biomarkers guidelines for NSCLC and is a standing member of the NCCN non-small cell lung cancer committee.

**D. Ross Camidge, MD, PhD**

Professor, Division of Medical Oncology
 Joyce Zeff Chair in Lung Cancer Research
 University of Colorado Denver School of Medicine
 Denver, CO

D. Ross Camidge, MD, PhD, has been the director of the thoracic oncology clinical and clinical research programs at the University of Colorado (CU) since 2007. Thoracic oncology encompasses predominantly lung cancer (both small cell and non-small cell), mesothelioma and thymic cancers. The standard treatment for many of these cancers have undergone a revolution in the last few years, particularly in relation to the use of personalized medicine, meaning running a series of specific tests to look for what is driving the cancer, and then tailoring drug treatments to each cancer's specific genetic weakness. With multiple successes to its name, the CU program has really established itself as one of the premier sites for leading this approach. In addition, every physician in the thoracic oncology program works as part of a highly functional multidisciplinary team, working very closely with all colleagues in other relevant specialties, including thoracic surgery, radiation oncology, and pulmonology, to deliver personalized medicine in a different way: developing a personal treatment plan for each patient. This approach affords the optimal use of every possible modality, often pushing the envelope in terms of new developments, to maximize the chances of prolonging control or curing each person's cancer. Beyond the medicine, Dr. Camidge also believes physicians should look after every patient, and their friends and family, as they would want their own friends and family to be looked after. He takes pride in the personal touch of highly informed and highly skilled schedulers and navigators, and applauds the honesty and expertise of clinic nurses and faculty. Dr. Camidge believes cancer is a tough diagnosis for everyone involved, and advocates for the day-to-day business of caring for patients with cancer to be as positive an experience as possible.

**Balazs Halmos, MD, MS**

Professor of Clinical Medicine

Director, Thoracic/Head and Neck Oncology

Director, Clinical Cancer Genomics

Albert Einstein College of Medicine/Montefiore Medical Center

Bronx, NY

Balazs Halmos, MD, MS, is a thoracic oncologist specializing in the management of patients with malignancies of the thoracic cavity, such as lung and gastroesophageal cancers as well as thymoma. He is director of thoracic oncology and director of clinical cancer genomics at Montefiore. Halmos also oversees the thoracic clinical trials program of novel clinical studies at the Albert Einstein Cancer Center, and is spearheading the effort to develop a molecular testing paradigm for patients with cancer managed within the Montefiore Health System; this will ultimately facilitate a personalized approach to cancer treatments. His research focus is clinical studies of experimental therapeutics. He has a particular interest in clinical studies of targeted agents for the treatment of thoracic malignancies, as well as translational studies focused on different aspects of lung cancer biology, such as oncogenic tyrosine kinase targeting, resistance to chemotherapy, radiation, and targeted therapeutics.

**Julia Kathleen Rotow, MD**

Instructor in Medicine

Dana-Farber Cancer Institute

Boston MA

Julia Kathleen Rotow, MD, received her MD from the UCLA David Geffen School of Medicine. She completed her residency training in Internal Medicine at the Massachusetts General Hospital and her fellowship training in Hematology/Oncology at the University of California, San Francisco. As a thoracic oncologist at the Dana-Farber Cancer Institute her research interests include the development of targeted therapies and immunotherapies for the treatment of oncogene-driven lung cancer.

NOTES

NOTES

NOTES



ASCO Direct™

HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series

PER®
Physicians'
Education
Resource, LLC
gotoper.com

**CELEBRATE THE 40TH ANNIVERSARY
OF CFS® LIVE IN NYC**

**40th Annual
CFS**®

Chemotherapy Foundation
SYMPOSIUM

Innovative Cancer Therapy for Tomorrow®

SAVE
THE
DATE!

NOVEMBER 9 – 11, 2022

New York Marriott Marquis • New York, NY

In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit™.

 **100** EXPERT
FACULTY
MEMBERS

 **25** TUMOR
TYPES

 **3** DAYS

 **1** MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

PER®
Physicians'
Education
Resource, LLC
gotoper.com